Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 3/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661989 | 0.81 | PPARG (0.45) | — | |
| SCHEMBL668157 | 0.80 | PPARG (0.40) | — | |
| SCHEMBL662608 | 0.79 | PDE4A (0.43) | CCR2CCR5 | |
| SCHEMBL662918 | 0.79 | DHFR (0.36) | DHFRCCR2CCR5 | |
| SCHEMBL28784944 | 0.75 | PPARG (0.37) | PDE1APDE1BPDE1C | |
| SCHEMBL1894992 | 0.75 | ACHE (0.44) | — | |
| SCHEMBL1896359 | 0.72 | SLC33A1 (0.62) | — | |
| Bromide SCHEMBL1894527 | 0.71 | SLC33A1 (0.61) | — | |
| SCHEMBL1889927 | 0.71 | SLC33A1 (0.61) | — | |
| SCHEMBL1892339 | 0.71 | SLC33A1 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | KOWA COMPANY, LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | PPARA, PPARG, PPARD | PDE1A 1821/4885PDE1B 2407/4885PDE1C 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.